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Abstract 
Four cases of central nervous ystem involvement by granulocytic sarcoma (three intracranial nd one paraspi- 
nal) in children with acute nonlymphocytic leukemia (FAB M1 or M2 subtype) are presented, and therapeutic 
modalities are discussed. All tumors were noted at initial presentation with diagnosis being made on clinical 
and radiological findings without biopsy. All patients had karyotypic abnormalities: three had translocation 
of chromosomes 8 and 21, and one had an unspecified hypodiploid clone. The three patients who developed 
intracranial tumors responded well to triple agent (cytosine arabinoside, hydrocortisone, and methotrexate) 
intrathecal chemotherapy and systemic chemotherapy, with or without local irradiation, as evidenced by rap- 
id disappearance of the tumors. Two children are disease-free after 17 and 57 months. One patient with 
paraspinal tumor failed to achieve a systemic remission but had no evidence of granulocytic sarcoma t 
autopsy. Thus, the prognosis of CNS granulocytic sarcoma is not uniformly gloomy if treated aggressively 
by combined modalities. The value of surgical intervention i terms of primary management, however, is 
limited. 
Introduction 
Granulocytic sarcoma (chloroma) is an ex- 
tramedullary accumulation of predominantly 
primitive cells of the myeloid series that tends to 
occur in younger patients with acute nonlym- 
phocytic leukemia (ANLL) [1 - 3]. This tumor 
type can develop at any body site but most com- 
monly occurs in the tissues of the orbital region, 
bone, soft tissue, skin, and sinuses. Involvement of 
the central nervous ystem (CNS) by granulocytic 
sarcoma has been considered to be unusual. How- 
ever, the frequency is expected to increase because 
of therapeutic advances in systemic therapy. The 
optimal management of this tumor remains to be 
established; experience has thus far been limited 
because of small patient numbers. We present four 
cases of CNS granulocytic sarcoma that were pres- 
ent at diagnosis in childhood ANLL. Other case 
reports are reviewed to better elucidate the 
biological and clinical significance of this com- 
plication of leukemia. 
Materials and methods 
The medical records of all patients, aged 15 years 
or younger, who were treated for ANLL in the 
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Department of Pediatrics, The University of Texas 
M.D. Anderson Hospital and Tumor Institute at 
Houston between 1970 and 1985, were reviewed to 
document intracranial or paraspinal granulocytic 
sarcoma (chloroma), defined as CNS granulocytic 
sarcoma. The diagnosis of ANLL was based on 
morphological, cytogenetic, and cytochemical ex- 
aminations that included periodic acid-Schiff 
(PAS), myeloperoxidase, naphthol AS-D 
chloroacetate esterase, and nonspecific esterase 
staining of initial bone marrow smears. Clot sec- 
tions of bone marrow aspirates were studied with 
light and electron microscopy. The French- 
American-British (FAB) classification system of 
ANLL [4] was performed on all patients registered 
after 1977. Specimens were submitted for 
cytogenetic studies on the majority of the patients 
registered after 1975. Chromosome analyses were 
performed on bone marrow aspirates obtained at 
the time of diagnosis. The techniques employed 
have been previously reported [5]. The bone mar- 
row cells were cultured overnight in Ham's F10 
medium supplemented with 20% fetal bovine 
serum. No mitotic stimulants were used. G-banding 
procedures were utilized on the chromosome 
preparations following a trypsin pretreatment. A 
maximum of twenty-five metaphases were analyzed 
and the results were reported according to the Inter- 
national System of Human Cytogenetic 
Nomenclature. 
The diagnosis of granulocytic sarcoma was based 
on clinical findings and radiologic examinations, 
including computed tomography (CT) scanning 
and myelography. Lumbar puncture was routinely 
performed at presentation of the disease and 
thereafter at regular intervals. Cerebrospinal fluid 
was evaluated for malignant cells by cytocen- 
trifugation followed by Wright-Giemsa staining. 
Results 
A review of the records of 108 children admitted to 
M.D. Anderson Hospital between 1970 and 1985 
with acute nonlymphocytic leukemia showed that 
17 of the children (15.7%) developed granulocytic 
sarcoma (chloroma) in the orbital area, soft tissue, 
lymph node, mediastinum, brain, paraspinal re- 
gion, skin, or bone. Karyotypic abnormalities were 
observed in 9 of the 10 patients evaluated; 6 had a 
translocation i volving chromosomes 8 and 21. 
Four of 108 children that were treated for ANLL 
had CNS granulocytic sarcoma (three intracranial 
and one paraspinal). All tumors were present at 
diagnosis. All patients had cytogenetic abnor- 
malities in bone marrow karyotypes: three had 
translocation of chromosomes 8 and 21 and one 
had an unspecified hypodiploid clone. All 8;21 
translocations were also associated with missing sex 
chromosomes. Three patients were classified as 
having FAB M2 subtype ANLL and one had M1 
subtype. 
Three children received combined therapy in- 
cluding local irradiation, intrathecal chemotherapy, 
and systemic induction chemotherapy. Intrathecal 
chemotherapy consisted of methotrexate (MTX, 
12 mg/m2), hydrocortisone (HDC, 15 rag/m2), and 
cytosine arabinoside (Ara-C, 30mg/m2). One 
child received intrathecal chemotherapy and 
systemic induction chemotherapy without irradia- 
tion. No surgical intervention, either for diagnosis 
or decompression, was performed. 
Two of four patients are disease-free after 17 
and 57 months. One child with a lower paraspinal 
tumor died without having achieved a marrow 
remission, but autopsy revealed complete resolu- 
tion of the tumor; the other child died six months 
after the diagnosis. In two patients with in- 
tracranial granulocytic sarcoma, the tumor had 
regressed completely following primary intrathecal 
chemotherapy and systemic induction therapy and 
before cranial radiation therapy. In one case, regres- 
sion of the tumor was observed by CT scan within 
two weeks of initiation of systemic therapy and one 
course of IT medication. The presenting features of 
these four patients are summarized in Table 1, and 
illustrative case reports are presented. 
Case reports 
Case One 
A 14-year-old boy developed cellulitis of the leg. 
Laboratory examination disclosed the following: 
Table 1. Presenting features of patients with CNS granulocytic sarcoma: 1970 and 1985. 
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Case Age/Sex Peripheral blood Bone marrow 
No. (yr) blasts 
WBC Platelet (°70) 
( x 103/)1) ( x 103/)1) 
FAB Karyotype 
1 14/M 27.8 58 86 M2 
2 15/M 10.9 12 81 M2 
3 4/M 5.3 239 87 M1 
4 11/F 4.8 28 44 M2 
(45,X, - Y,t[8q - ;21q + ]) 
Hypodiploid (Not specified) 
(45,X, - Y,t[8q - ;21q + ]) 
(45,X, - X,t[8q - ;21 q + ]) 
yr, year; M, male; F, female; WBC, white blood cell; FAB, French-American-British classification for acute leukemia. 
WBC count, 27800/ml with 83°70 blasts; platelet 
count, 58000/ml, and hemoglobin, 9.7 g/dl. Bone 
marrow aspiration biopsy revealed peroxidase and 
chloroacetate sterase positive, but nonspecific 
esterase and PAS-negative leukemic blasts. Acute 
nonlymphocytic leukemia (FAB M2 subtype) was 
diagnosed. Cytogenetic study of bone marrow cells 
revealed an abnormal karyotype, 
(45,X,-Y,t[8q- ;21q + ]). Cerebrospinal fluid was 
negative for leukemic ells. A routine CT scan of 
the brain was normal. 
Within 24 hours of admission, the patient devel- 
oped signs of lower spinal cord compression with 
bilateral paresis of the lower legs. Admission 
neurological examination had been normal. He 
then developed acute neurogenic bladder and loss 
of bowel function. An emergency myelogram 
revealed complete spinal block at the inferior level 
of T6. Radiation therapy was begun with 3 000 tad 
to the spine from T1 to Tg, followed by 
craniospinal irradiation using 2400 tad and 
systemic chemotherapy, including Ara-C and 
6-thioguanine. The patient regained some spon- 
taneous movement of the lower extremities but was 
unable to stand or walk unassisted. Although his 
general status improved with these therapies, no 
systemic remission could be induced. He died ll 
weeks after diagnosis. Results of autopsy 
demonstrated subdural and subarachnoid hemor- 
rhage of the brain and spinal cord; however, no 
evidence of local, residual leukemic infiltration was 
found. 
Case Three 
A four-year-old boy who was in good health until 
April 1982, when he developed a left otitis media, 
which was treated by oral antibiotics. One week 
later he began complaining of headache and was 
noted to have drooping of the left side of the face. 
A maxillary tumor was found. A biopsy was inter- 
preted as malignant lymphoma nd he was referred 
to M.D. Anderson Hospital. Physical examina- 
tion revealed marked swelling of the left side of the 
face associated with left facial nerve palsy. Bilateral 
papilledema was also noted. The liver and spleen 
were not palpable. Laboratory evaluation revealed 
the following; WBC count, 5300/ml with 39°70 
blasts; hemoglobin, 8.7 g/dl; and platelet count, 
239000/ml. Bone marrow was infiltrated with blast 
cells strongly positive for peroxidase and esterase 
stains. Numerous Auer bodies were also noted. 
Periodic acid-Schiff and nonspecific esterase stains 
were negative. A cytogenetic study revealed the 
presence of (45,X,-Y,t[8q-;21q + ]). A diagnosis of 
ANLL (FAB M1 subtype) was made. Pathological 
review of the maxillary tumor was consistent with 
granulocytic sarcoma. A skull X ray revealed mark- 
ed spitting of the cranial sutures, presumably 
secondary to increased intracranial pressure. Com- 
plete opacification of the left maxillary sinus was 
also noted. ACT scan of the head disclosed amass 
in the left maxillary sinus extending into the left na- 
sal cavity with destruction of the medial wall. Fur- 
thermore, lobulated intracranial masses were also 
noted in the left temporal, frontal, and parietal 
regions, all of which markedly enhanced with con- 
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trast medium (Fig. 1). Although no 
histopathological documentation of intracranial 
tumor was available, a myeloblastic origin was 
assumed in view of the clinical course. The patient 
was started on systemic chemotherapy, including 
vincristine, Ara-C, and dexamethasone, and radia- 
tion therapy using 3000 rad to the skull and max- 
illa. Prompt response to these measures was 
evidenced by complete disappearance of the tumors 
in the maxillary sinus and brain (Fig. 2). The fin- 
ding of increased intracranial pressure precluded a
lumbar puncture at the initial work-up; it was per- 
formed four weeks later for the first time, and the 
results were normal. After a hematologic remission 
was obtained, the patient was treated on cyclic 
maintenance chemotherapy for 18 months. He re- 
mains in initial complete remission 57 months after 
the diagnosis. A follow-up CT scan is shown in 
Fig. 3. This child has learning disabilities. He is 
currently in special education classes and required 
two years to complete kindergarten. 
Fig. 2. Complete disappearance of the tumors in the maxillary 
sinus and brain occurred following skull irradiation therapy and 
systemic hemotherapy (July 19, 1982). 
Fig. 1. Multiple, lobulated intracranial tumors were observed in 
the left temporal and frontal obes with marked enhancement by 
injected contrast medium (June 24, 1982). 
Fig. 3. Follow-up CT scan of the brain showed marked dilata- 
tion of the cortical sulci and focal area of atrophy of the brain 
(June 13, 1985). 
Case Four 
An eleven year old girl developed headaches, chest 
pain and progressive pallor. A complete blood 
count showed hemoglobin 3.2 gm%0, white blood 
count 4800/ml with 36% blasts, and platelets 
28 000/ml. Symptoms resolved with a transfusion 
of packed red cells. A bone marrow aspirate show- 
ed FABM2 Auer rod positive blasts which were 
perioxidase, PAS, choroacetate esterase and Tdt 
positive. A cytogenetic analysis howed the pres- 
ence of 45, X, -X, t[Sq;21q+] blasts. She was 
begun on systemic induction with daunorubicin, 
Ara C and 6TG; a single intrathecal injection of 
methotrexate, Ara C and hydrocortisone was ad- 
ministered. Cerebrospinal fluid cytology was 
negative. A routine CT scan showed a modular 
contrast enhanced tumor adjacent o the lateral 
ventricle. A follow up CT scan done 3 weeks later 
showed marked resolution of the mass. Her induc- 
tion regimen was repeated; intrathecal 
chemotherapy was also administered. A follow up 
CT scan showed complete resolution. More inten- 
sive intrathecal chemotherapy along with cranial 
irradiation was then given. Follow up CT scan done 6 
months from diagnosis howed no evidence for 
recurrence. She remains in CNS and marrow remis- 
sion. She has not received further therapy directed 
at the CNS. 
Discussion 
Granulocytic sarcomas usually develop in patients 
with a known diagnosis of nonlymphocytic 
leukemia, although development of tumors may 
precede the diagnosis of leukemia [6-10]. 
Routine morphological methods are limited for 
making a definitive pathologic diagnosis of these 
tumors. Naphthol AS-D chloroacetate sterase 
staining seems to be the most conclusive yet 
simplest method for differential diagnosis [10], 
especially when applied on freshly prepared slides 
[11], and should be included in the diagnostic work- 
up. Although reported survival rates of patients 
who developed granulocytic sarcoma ppear to be 
similar to survival rates of patients without hose 
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tumors [6, 9], the ultimate prognosis has been in- 
variably poor in pediatric patients [2, 3, 8]. The tu- 
mor develops at various stages of nonlymphocytic 
leukemia with a reported frequency ranging from 
2.9 to 6.8% [2,9,12]. Major progress in the treat- 
ment of ANLL has occured uring the past decade; 
more than 25% of children with ANLL have been 
in initial complete remission for two years with in- 
tensive therapy [13-16]. Thus, the actual frequency 
of granulocytic sarcoma is probably higher than 
reports uggest. We have observed evelopment of
granulocytic sarcoma in 17 of 108 children (15.7%) 
with ANLL in a 16-year period of time (Unpublish- 
ed data). 
The reported frequency of CNS involvement in
ANLL ranges from 25 to 38% [17-18], but most 
cases involve diffuse meningeal infiltration. The ac- 
tual occurrence of CNS granulocytic sarcoma is 
unusual. None of 323 patients with ANLL reported 
by Muss and Moloney [12] developed intracranial 
tumors, although two of them developed 
paraspinal tumors. Liu et al. [2] reported that five 
of 338 patients with myelogenous leukemia devel- 
oped intracranial tumors. Neiman et al. [10] 
reported that among 61 biopsy-proven granulocytic 
sarcomas, seven developed in the vertebral and 
paravertebral regions, and only one tumor devel- 
oped in the brain. A recent report by Pui et al. [19] 
from St. Jude Children's Research Hospital 
documented that two of 184 children with ANLL 
developed intracerebral mass. They also reported 
the development of paraspinal granulocytic sar- 
coma in one of 309 children with ANLL at presen- 
tation [20] and two of 297 children throughout 
their course of ANLL [21]. In 1981, Petursson and 
Boggs [22] reviewed 67 previously published cases 
of spinal cord involvement in leukemia patients and 
found that 31 had acute myeloid leukemia. Clinical 
features and therapeutic modalities in well- 
documented recent reports of CNS granulocytic 
sarcoma re summarized in Table 2 [2, 6, 7, 20, 
22-32]. Most of the previously published cases of 
CNS granulocytic sarcoma developed in older pa- 
tients; the clinical and biological significance of 
this complication of leukemia in pediatric patients 
is obscure. In our series, CNS involvement by 
granulocytic sarcoma was found at diagnosis in 
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four of 108 children with ANLL. In previous 
publications most of the CNS tumors developed 
months after the initial diagnosis of ANLL. 
Previous reports on patients with intracranial 
granulocytic sarcoma have indicated that the pro- 
gress of the disease in the adult population is 
relatively slow, as shown in Table 2. All intracranial 
tumors that developed in three patients reported by 
Pippard et al. [30] were highly sensitive to radiation 
therapy; two of the patients urvived 34 + and 22 + 
months after the tumor developed. The patients 
reported by Hurwitz et al. [7] and Ballard et al. [24] 
survived 18 months and 31 months after the 
development of intracranial granulocytic sarcoma. 
In our study, two of three patients with intracranial 
tumor survived: one has been followed 57 months 
after the initital diagnosis of leukemia (41 months 
after discontinuation f all therapy). 
Most reports have indicated that patients with in- 
tracranial tumors benefit from radiation therapy, 
with or without intrathecal chemotherapy [6, 7, 
30]. Chemosensitivity of granulocytic sarcoma has 
not been completely evaluated, although it was sug- 
gested in some reports [6, 35]. In our study, two pa- 
tients were treated with intrathecal therapy and 
systemic hemotherapy without radiation therapy. 
Notably, Case 4 received only a single course of tri- 
ple intrathecal therapy in addition to systematic 
chemotherapy including continuous infusion of 
Ara-C. Ara-C is known to be effective for preven- 
tion and treatment of CNS leukemia. Intrathecal 
chemotherapy, employing three drugs or Ara-C 
alone, may have tumoricidal ability, although in- 
trathecal methotrexate alone seems to be ineffective 
[25]. Considering the high chemosensitivity of the 
tumors observed in our patients, whole skull ir- 
radidation could concievably be excluded from the 
primary treatment, particularly in younger pa- 
tients, to avoid adverse ffects of the therapy on the 
immature brain. 
Computed tomography scanning plays a major 
role in the diagnosis of CNS granulocytic sarcoma 
because of the tumor's relatively consistent ap- 
pearance. On CT scanning, it is usually seen as a 
mass with increased attenuation with surrounding 
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edema, which is uniformly enhanced following in- 
jection of contrast material [28, 29, 34]. Based on 
these findings and the clinical information, a 
preliminary diagnosis can be made and confirmed 
when there is a dramatic response to therapy. 
Routine surveillance of the CNS system by CT 
scanning should be included in the initial 
diagnostic workup in children with ANLL. 
Laboratory evaluation of CSF has only limited val- 
ue in the diagnosis of intracranial granulocytic sar- 
coma. 
Extensive reviews of paraspinal granulocytic sar- 
coma have been published [22, 35]. The tumor may 
be the presenting symptom of leukemia nd may be 
confused with primary orthopedic disease. Upon 
development of paraspinal granulocytic sarcoma, it
is important to establish an early diagnosis and ad- 
minister proper therapy to prevent permanent 
neurological damage from spinal cord compression 
by the tumor [36]. Even then, as shown by our 
Case 1, rapid recognition and treatment may not be 
successful. Myelography is the primary diagnostic 
procedure for defining disease xtension. However, 
a lumbar puncture procedure may aggravate the 
neurological dysfunction and be disadvantageous to 
the patient. Considering the high chemo- and 
radiosensitivity of this type of tumor [22], 
paraspinal granulocytic sarcoma should be 
primarily treated by high-dose corticosteroids 
followed by systemic hemotherapy and radiation 
therapy. 
There has been no comprehensive study of the 
karyotypic abnormalities in patients with CNS 
granulocytic sarcoma. In our study, all four 
children who developed CNS granulocytic sarcoma 
also had abnormalities in the karyotype; three had 
translocation of chromosomes 8 and 21, and one 
had an unspecified hypodiploid clone. Leukemia 
associated with 8;21 transloeation is known to have 
a good prognosis [37, 38] but also is closely related 
to the development of granulocytic sarcoma 
[39-41]. The relatively benign course of ANLL 
observed in patients with CNS granulocytic sar- 
coma may often be explained by the frequent 
association of this particular karyotypic hange. 
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